OBN BioIntelligence offers unique access to an enviable database of contacts and knowledge, not available through any commercial source.
Targeted calls to our 400-plus Membership can uncover assets, capabilities or knowledge within a specified area of partnering interest. OBN compiles responses, combining these with the results of any additional commissioned research, for analysis and action by BD&L teams. OBN can facilitate contact between interested parties where required.
Projects carried out for European, Asian and US pharma clients have yielded responses from between 15 and 50 companies in related areas.
For further information about OBN BioIntelligence, email John Harris, CEO, or Jonathan Rohll, Analyst at OBN.